Treatment of Clinically Significative diabetic Macular Edema: influence of Bevacizumab, Triamcinolone and the combination of both plus macular grid thermal laser Photocoagulation of subthreshold

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10939948

Enrollment

Registered

2007-05-15

Start date

2007-01-01

Completion date

Unknown

Last updated

2021-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic clinically significative diffuse macular edema Eye Diseases Macular edema

Interventions

Avastin group: intravitreal Bevacizumab 0.05 ml and then the same dose one and a half months later if edema is detected in Optical Coherence Tomography (OCT) Triamcinolone group: intra

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diabetic CSME not treated previously 2. Best Corrected Visual Acuity (BCVA) less than 20/40 3. Patient able to complete follow-up 4. Controlled diabetes

Exclusion criteria

Exclusion criteria: 1. Other associated ocular pathology 2. Ocular surgery three months before the inclusion 3. Participating in other interventional studies

Design outcomes

Primary

Measure	Time frame
Visual acuity comparison	—

Secondary

Measure	Time frame
1. Macular visual field comparison 2. OCT variations of edema	—

Countries

Spain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026